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 Eosinophilia in asthma: the easy way is not always the best 
Bianca Beghè, Antonio Spanevello, Leonardo M. Fabbri 
 
According to the latest version of the GINA Strategy document
1
, asthma is considered a 
heterogeneous disease with clinical manifestations sustained by different molecular mechanisms; in 
particular, these manifestations may be (but are not invariably) associated with chronic airway 
inflammation
1
. Indeed, part of the heterogeneity of asthma may be due to different intensities or 
patterns (eg eosinophilic vs neutrophilic) of airway inflammation
2
. 
The search for asthma phenotypes is an attempt to identify specific patient groups with 
homogeneous functional and inflammatory characteristics that may relate to clinical manifestations, 
prognosis, and/or response to treatment
2
. 
The eosinophilic asthma phenotype accounts for the majority of patients, and airway eosinophilia is 
indeed a marker of (i) severity of asthma, (ii) lack of asthma control, and (iii) responsiveness to 
steroids
2,3
. However, the importance of identifying eosinophilia in clinical practice is hampered by the 
lack of a simple, reliable and reproducible method of  measuring it.   
Eosinophilic inflammation in asthma has been assessed with invasive procedures such as biopsies 
and bronchoalveolar lavage
4
, and with noninvasive methods such as peripheral blood cell count or 
biomarkers (eg eosinophil cationic protein, osteocalcin), induced sputum, and fractional exhaled nitric 
oxide (FeNO)
5-7
. While bronchial biopsy specimens represent the “gold standard” in terms of the target 
organ, induced sputum has emerged as the best proxy for clinical studies. This is both because it is the 
closest to bronchial biopsy specimens and/or lavage
4,7
, and because it is noninvasive and relatively easy 
to standardize for use in clinical practice
8
. Still, significant concerns remain about the feasibility of 
measuring induced sputum in regular laboratories and, more important, about its reproducibility
8
. 
The paper by Korevaar et al. in this issue of the Journal addresses the important  questions of 
sensitivity, specificity and predictive value of various surrogate markers for airway eosinophilia, 
assuming sputum eosinophilia to be the gold standard
9
. The investigators performed a meticulous  
systematic review and a meta-analysis that included 24 studies in adults and 8 in children. They analyzed 
FeNO, blood eosinophils, and serum total IgE—all of which have moderate diagnostic accuracy—as 
minimally invasive markers of airway eosinophilia. Most of the studies used induced sputum as a 
reference . The authors indicate that FeNO, blood eosinophils and IgE, if considered alone, have lower 
sensitivity and specificity than does induced sputum in identifying eosinophilic airway inflammation. 
Based on these results, Korevaar et al. state that no single surrogate marker should be used to guide 
treatment.  Measurement of blood eosinophils would undoubtedly be the simplest way to evaluate 
eosinophilic inflammation, but Schleich et al. recently described asthmatic patients with significant 
dissociation between blood and airway eosinophilia
5
. Korevaar et al., therefore, conclude that measuring 
sputum eosinophils is still the best method of identifying eosinophilic airway inflammation.  
 Considering the limits of these methods, one might ask once again whether practicing clinicians 
should measure airway eosinophilia in asthmatics. Various studies have clearly shown that therapy 
based on a count of sputum eosinophils is statistically more effective in controlling asthma than are 
clinical or functional measurements
6
. However, these studies were conducted in single specialized 
centres and in small groups of subjects. A larger intervention study conducted in unselected asthmatic 
subjects confirmed that sputum eosinophils can be used to assess the anti-inflammatory effect of 
treatment
10
, but the variability in their results (as clearly illustrated in panel C of Figure 1) makes this 
method not applicable to individuals. In contrast, studies conducted in highly selected severe asthmatics 
with steroid-resistant sputum and circulating eosinophils have clearly shown that specific anti-
eosinophilic treatment (anti-IL5, anti-IL5R, anti-IL4, anti-IL13) is highly effective both in reversing 
eosinophilia and in reducing exacerbations
11
. However, it is still unclear whether, even in these highly 
selected steroid-resistant asthmatics, eosinophils need to be measured in sputum; it appears that it 
might be sufficient to measure them in peripheral blood. Considering that new biological agents will soon 
become available for treatment of steroid-resistant eosinophilic asthmatics at risk of exacerbations
11
, 
these patients will probably be the only ones in whom the assessment of eosinophilia will become 
mandatory. In this difficult population, it is possible that the use of these biological agents will be 
restricted to highly specialized centres where sputum eosinophilia can be reliably performed.    
In conclusion, Korevaar’s study points out significant differences in the accuracy of surrogate markers of 
airway inflammation. It also confirms that induced sputum is still the best non-invasive technique for 
evaluating new markers of eosinophilic airway inflammation because of its sensitivity and specificity. 
However, the variability between subjects reduces the usefulness of this method in clinical practice and 
confines it to selected patients followed in specialized centres. Measuring single surrogate markers of 
airway eosinophilic inflammation may therefore be an easy way to assess eosinophilic airway 
inflammation, but it is not necessarily the best one, and it is certainly not yet ready for use in clinical 
practice. 
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Figure 1. Line plot of differential eosinophil counts in sputum. Showing individual profiles and time 
trends in two groups of asthmatic patients, one treated with inhaled high fixed dose budesonide/ 
formoteriol and the other with inhaled budesonide/formoterol mantainance and reliever therapy 
Individual profiles show large variability of % eosinophils in sputum. Modified from reference 10. 
